查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2008357

惡性間皮癌市場：依治療方法、藥物類別、治療階段、給藥途徑和最終用戶分類－2026-2032年全球市場預測

Malignant Mesothelioma Market by Treatment Type, Drug Class, Line Of Therapy, Route Of Administration, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，惡性間皮癌市值將達到 9.0516 億美元，到 2026 年將成長至 9.8667 億美元，到 2032 年將達到 16.0715 億美元，年複合成長率為 8.54%。

主要市場統計數據
基準年（2025 年） 9.0516億美元
預計年份（2026年） 9.8667億美元
預測年份（2032年） 16.0715億美元
複合年成長率 (%) 8.54%

這本權威的惡性間皮癌入門書籍系統地說明了臨床負擔、診斷複雜性、不斷發展的多學科治療途徑以及臨床和商業性決策的戰略挑戰。

惡性間皮癌仍是一種複雜的腫瘤疾病，晚期，組織學異質性高，且對臨床治療和患者生活品質影響顯著。診斷過程越來越依賴影像學、病理學和分子譜分析的整合，以區分組織學亞型並識別可治療標靶。同時，多學科腫瘤會診在製定治療策略方面發揮著至關重要的作用，這些策略應與患者的功能狀態和意願相符。

對重塑間皮瘤治療的變革性變化進行了全面回顧，包括免疫腫瘤學、精準標靶治療、監管趨勢、保險公司准入趨勢和研發優先事項方面的突破。

間皮瘤的醫療格局正在經歷一場變革，其驅動力包括科學突破、監管調整以及保險公司和醫療服務提供者期望的轉變。免疫腫瘤藥物在特定患者族群中展現的持續療效正在重塑治療模式，促使人們重新評估治療順序和合併治療策略。同時，利用腫瘤特異性生物標記的標靶治療正在重新定義臨床研發的重點，並有助於在診斷時進行更詳細的分子特徵分析。

對 2025 年美國關稅措施對間皮瘤治療的供應鏈、臨床應用、研究合作、製造成本和商業營運的累積影響進行重點分析。

美國2025年實施的關稅調整對全球藥品供應鏈、臨床用藥途徑以及與間皮瘤治療相關的合作研究計畫產生了複雜的影響。這些措施可能會影響進口活性藥物成分、特殊醫療設備及相關耗材的成本基礎，進而影響跨國研發公司和契約製造製造商的生產策略和庫存管理。

從富有洞察力的細分視角來看，治療方法、藥物分類、治療階段、給藥途徑和最終用戶觀點如何全面決定發展重點和患者照護路徑。

細分市場分析揭示了各種臨床和商業性因素如何相互作用，從而影響投資重點和患者治療路徑。基於治療類型，市場研究涵蓋化療、免疫療法、放射線治療、手術和標靶治療。化療進一步細分為Pemetrexed聯合治療和含鉑類藥物藥療法。免疫療法進一步細分為CTLA-4抑制劑和PD-1抑制劑。標靶治療進一步細分為EGFR抑制劑、中鏈絲胺酸標靶藥物和VEGF抑制劑。了解這些治療方法之間的差異有助於明確哪些領域可能出現創新，以及哪些臨床族群最有可能從新型聯合治療中獲益。

本次演講將說明美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和策略機遇，重點在於臨床實踐、報銷框架、供應彈性和共同研究模式。

細微的區域差異對研究合作、臨床應用和商業策略有顯著影響。在美洲，成熟且有效率的研究中心和整合式醫療網路能夠使臨床試驗結果迅速應用於臨床實踐；然而，由於支付方環境各異，需要對價值進行細緻入微的論證才能實現廣泛應用。相較之下，歐洲、中東和非洲地區的監管和報銷環境則存在差異，通常以集中核准系統和各國間准入機會不均為特徵。這不僅為跨區域合作提供了機遇，也為一致推廣帶來了挑戰。

重點關注公司層面的關鍵洞察，包括競爭定位、產品線差異化、策略夥伴關係、製造能力和商業化策略，這些策略推動了整個間皮瘤治療產品組合的創新。

間皮瘤領域的企業發展趨勢取決於各企業如何將研發管線創新與生產能力、監管策略和商業性執行結合。領導企業憑藉其構建引人入勝的臨床故事的能力脫穎而出，這些故事以獨特的作用機制、有意義的生物標記項目以及可靠的安全性和有效性數據為支撐。中型創新企業通常追求靈活的聯合治療策略和針對特定適應症的治療，而大型企業則利用規模優勢來支持後期研發和複雜的全球應用。

為行業領導者提供實用的管理建議，以加速治療方法創新、最佳化打入市場策略、加強與支付方和醫療保健提供者的合作，並建立有彈性的供應和研發系統。

產業領導者應將短期商業決策與長期策略目標結合，以加速間皮瘤治療取得實質進展。首先，應優先發展以生物標記主導的研發，並將轉化終點納入早期臨床試驗，使後期計畫能夠精準鎖定可能對治療產生反應的患者群體，並降低研發過程中的脫落率。其次，應設計適應性試驗框架和平台研究，以高效評估聯合治療，從而更快地發現具有協同作用的治療方法，同時節省患者和經濟資源。

透明的調查方法概述了資料收集方法、分析框架、專家諮詢參與、檢驗通訊協定以及用於整合臨床、監管和商業性發現的局限性。

本研究途徑結合了與第一線專家的合作、有針對性的文獻整合以及結構化的分析框架，從而確保了研究結果的可靠性和說服力。我們諮詢了臨床腫瘤學、病理學、監管事務和供應鏈管理領域的專家，以檢驗假設、解讀新的臨床數據並提取營運方面的啟示。同儕審查的文獻、監管指導文件和會議論文集提供了有關治療和診斷趨勢的臨床和科學證據。

最終結論：整合各方力量，明確戰略轉折點、相關人員的責任、政策考慮以及未來優先事項，以改善患者預後和推進治療。

這份概要凸顯了一個明確的迫切需求：間皮瘤治療的進展需要診斷、治療創新和醫療服務取得途徑等方面的協調發展。儘管免疫腫瘤學和標靶治療的科學進步前景廣闊，但患者預後的持續改善取決於精準的患者篩選、嚴謹的證據生成以及將臨床試驗結果轉化為常規臨床實踐的能力。因此，相關人員必須在研發、監管和支付方等不同領域合作，以確保獎勵與證據要求相符。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 市佔率分析（2025 年）
  • FPNV定位矩陣（2025）
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響（2025 年）

第7章：人工智慧的累積影響（2025 年）

第8章惡性間皮癌市場依治療方法分類

  • 化療
    • Pemetrexed聯合治療
    • 含鉑類藥物單藥療法
  • 免疫療法
    • CTLA-4抑制劑
    • PD-1抑制劑
  • 放射線治療
  • 外科手術
  • 分子標靶治療
    • EGFR抑制劑
    • 標靶藥物
    • VEGF抑制劑

第9章：惡性間皮癌市場：依藥物類別分類

  • 抗葉酸
  • 免疫查核點抑制劑
    • CTLA-4抑制劑
    • PD-1抑制劑
    • PD-L1抑制劑
  • 激酶抑制劑
  • 單株抗體
  • 鉑製劑

第10章：惡性間皮癌市場：依治療階段分類

  • 第 1 行
  • 第二行
  • 從第三行開始

第11章：惡性間皮癌市場：依給藥途徑分類

  • 腹腔內
  • 靜脈
  • 口服

第12章：惡性間皮癌市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 專科診所

第13章惡性間皮癌市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章惡性間皮癌市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：惡性間皮癌市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國惡性間皮癌市場

第17章：中國惡性間皮癌市場

第18章 競爭格局

  • 市場集中度分析（2025 年）
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析（2025 年）
  • 產品系列分析（2025 年）
  • 基準分析（2025 年）
  • AbbVie Inc.
  • Advanz Pharma Corp.
  • Argenx SE
  • AstraZeneca Plc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Emcure Pharmaceuticals Limited
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi AG
  • Karyopharm Therapeutics Inc.
  • Merck & Co., Inc.
  • Mylan NV
  • Nichi-Iko Pharmaceutical Co., Ltd
  • Novartis AG
  • Novocure GmbH
  • Ono Pharmaceutical Co. Ltd
  • Pfizer Inc.
  • Polaris Pharmaceuticals, Inc.
  • Sanofi SA
  • Sun Pharmaceuticals Industries Ltd
  • Wellona Pharma
Product Code: MRR-C002B1C99564

The Malignant Mesothelioma Market was valued at USD 905.16 million in 2025 and is projected to grow to USD 986.67 million in 2026, with a CAGR of 8.54%, reaching USD 1,607.15 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 905.16 million
Estimated Year [2026] USD 986.67 million
Forecast Year [2032] USD 1,607.15 million
CAGR (%) 8.54%

An authoritative introduction to malignant mesothelioma that frames clinical burden, diagnostic complexity, evolving multidisciplinary care pathways, and strategic imperatives for clinical and commercial decision-making

Malignant mesothelioma remains a complex oncologic entity characterized by late-stage presentation, histologic heterogeneity, and significant implications for clinical management and patient quality of life. Diagnostic pathways increasingly rely on integrated imaging, pathology, and molecular profiling to distinguish histologic subtypes and identify actionable targets, while multidisciplinary tumor boards play a pivotal role in aligning therapeutic intent with functional status and patient preferences.

Advances in systemic therapies and surgical techniques have expanded the clinical toolkit, yet meaningful improvement in long-term outcomes requires coordinated advances across diagnostics, therapeutic development, and care delivery. Consequently, clinicians, biopharma developers, and payers must navigate an environment of evolving evidence, shifting regulatory expectations, and pressure to demonstrate real-world effectiveness. This introduction frames the ensuing analysis by establishing the disease context, the principal clinical challenges, and the strategic imperatives that shape research investments and commercialization approaches.

Throughout the report, emphasis is placed on translating clinical insights into operational priorities. Early and accurate diagnosis, alignment of clinical trial design with unmet needs, and integration of patient-reported outcomes into development programs are highlighted as critical vectors for improving care. By situating the reader within this clinical and commercial landscape, the introduction provides the foundation required for informed decision-making across research, development, and market access functions.

A comprehensive review of the transformative shifts reshaping mesothelioma care, encompassing immuno-oncology breakthroughs, precision-targeted agents, regulatory momentum, payer access dynamics, and R&D prioritization

The mesothelioma landscape is undergoing transformative shifts driven by scientific breakthroughs, regulatory recalibration, and changing expectations from payers and providers. Immuno-oncology agents have reoriented therapeutic paradigms by demonstrating durable responses in subsets of patients, prompting reconsideration of sequencing and combination strategies. In parallel, targeted therapies that exploit tumor-specific biomarkers are reshaping clinical development priorities and encouraging more granular molecular characterization at diagnosis.

Regulatory bodies are increasingly receptive to adaptive development pathways and real-world evidence to support approval and labeling decisions, which accelerates time-to-patient for promising therapies but also raises the bar for post-approval evidence generation. Meanwhile, payer and provider stakeholders demand clearer demonstration of value through comparative effectiveness, patient-centric outcomes, and cost-of-care considerations, which in turn influences trial design and market access strategies.

Operationally, these shifts require more integrated translational pipelines, earlier engagement with regulatory and reimbursement authorities, and stronger alliances between academic centers, biotechnology firms, and community providers. Enhanced diagnostic stratification, combination modality research, and a focus on survivorship and supportive care metrics will be defining features of the next wave of progress. As a result, stakeholders must adapt business models to support adaptive trials, flexible commercial strategies, and robust evidence generation that extends beyond traditional randomized controlled trial endpoints.

A focused analysis of the cumulative impact of United States tariff measures in 2025 on mesothelioma therapeutic supply chains, clinical access, research collaborations, manufacturing costs, and commercial operations

The introduction of tariff adjustments in the United States during 2025 has created a complex set of implications for global pharmaceutical supply chains, clinical access pathways, and collaborative research programs that are relevant to mesothelioma therapies. These measures can influence the cost base for imported active pharmaceutical ingredients, specialized devices, and ancillary supplies, which, in turn, affect manufacturing strategies and inventory management across multinational developers and contract manufacturers.

Clinically, any supply disruption or cost escalation can translate into allocation pressures for high-cost therapies and influence institutional formulary decisions. Payers and providers may seek more stringent procurement terms, prioritize domestically sourced products where feasible, or request enhanced pricing transparency and outcomes-based contracting to preserve access. Moreover, cross-border research collaborations can face administrative friction if tariff-associated costs alter budget projections or complicate material transfer arrangements between international partners.

From an operational perspective, biopharma organizations are responding by reassessing supplier diversification, onshoring critical production steps where economically viable, and negotiating long-term procurement agreements to buffer volatility. Meanwhile, regulatory and compliance teams are aligning contracts and quality assurance processes to accommodate evolving trade measures. Taken together, these adjustments underscore the need for integrated commercial, supply chain, and clinical strategies to preserve therapy availability and ensure that patient access remains the guiding priority during periods of trade policy change.

Insightful segmentation-driven perspectives revealing how treatment modality, drug class, line of therapy, route of administration, and end-user dynamics collectively define development priorities and patient care pathways

Segmentation analysis reveals how divergent clinical and commercial vectors interact to shape investment priorities and patient pathways. Based on Treatment Type, market is studied across Chemotherapy, Immunotherapy, Radiotherapy, Surgery, and Targeted Therapy. The Chemotherapy is further studied across Pemetrexed Combinations and Platinum Monotherapy. The Immunotherapy is further studied across Ctla-4 Inhibitors and Pd-1 Inhibitors. The Targeted Therapy is further studied across Egfr Inhibitors, Mesothelin Targeted Agents, and Vegf Inhibitors. Understanding these modality distinctions clarifies where incremental innovation will emerge and which clinical cohorts may derive disproportionate benefit from novel combinations.

Based on Drug Class, market is studied across Antifolates, Immune Checkpoint Inhibitors, Kinase Inhibitors, Monoclonal Antibodies, and Platinum Compounds. The Immune Checkpoint Inhibitors is further studied across Ctla-4 Inhibitors, Pd-1 Inhibitors, and Pd-l1 Inhibitors. This drug-class perspective highlights the scientific rationale guiding pipeline prioritization and illuminates the mechanisms most amenable to durable responses and tolerability improvements. Based on Line Of Therapy, market is studied across First Line, Second Line, and Third Line And Beyond, which frames strategic decisions around label positioning, comparator selection, and sequencing studies.

Based on Route Of Administration, market is studied across Intraperitoneal, Intravenous, and Oral, a classification that influences patient convenience, administration settings, and payer reimbursement policies. Based on End User, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics, which defines the distribution channels, purchasing dynamics, and service-line implications for adoption. By synthesizing these segmentation lenses, stakeholders can prioritize development paths that align with clinical unmet need, operational feasibility, and payer acceptability while anticipating where differential adoption will occur across care settings.

Regional dynamics and strategic opportunities across the Americas, Europe Middle East & Africa, and Asia-Pacific, highlighting differences in clinical practice, reimbursement frameworks, supply resilience, and collaborative research models

Regional nuances exert material influence on research collaboration, clinical implementation, and commercial strategy. In the Americas, established centers of excellence and integrated care networks facilitate rapid translation of clinical trial findings into practice, but diverse payer landscapes necessitate nuanced value demonstration for broad adoption. In contrast, Europe, Middle East & Africa presents heterogeneous regulatory and reimbursement environments, where centralized approvals often coexist with country-level access variability, creating both opportunities for pan-regional initiatives and challenges for consistent roll-out.

Meanwhile, Asia-Pacific is characterized by accelerating clinical research capacity, expanding biotech innovation, and variable reimbursement maturity across countries. Greater investment in regional manufacturing and localized clinical development is reshaping how global programs are designed and executed. Across all regions, differences in diagnostic infrastructure, pathology expertise, and provider training influence the speed at which novel therapies can be integrated into routine care.

Consequently, sponsors and health system leaders must calibrate regional strategies that account for these differences. Cross-regional collaboration around harmonized protocols, targeted real-world evidence collection, and capacity building in diagnostics can reduce time-to-adoption and improve equity in access. Strategic partnerships that leverage regional strengths while addressing local barriers will be critical for scaling impactful therapies and ensuring that improvements in clinical outcomes reach diverse patient populations.

Key company-level insights that spotlight competitive positioning, pipeline differentiation, strategic partnerships, manufacturing capabilities, and commercialization tactics driving innovation across mesothelioma treatment portfolios

Company-level dynamics within the mesothelioma space are defined by how organizations align pipeline innovation with manufacturing capacity, regulatory strategy, and commercial execution. Leaders differentiate through proprietary mechanisms of action, meaningful biomarker programs, and an ability to generate compelling clinical narratives supported by robust safety and efficacy profiles. Mid-size innovators often pursue nimble combination strategies or niche indications, while larger firms leverage scale to support late-stage development and complex global submissions.

Strategic partnerships and licensing arrangements remain central to accelerating clinical development and broadening geographic reach. Companies that structure collaborations with academic centers and contract research organizations to access specialized surgical techniques or unique patient cohorts can de-risk development and enhance evidentiary depth. Manufacturing competence, including capabilities for complex biologics or targeted agent production, increasingly informs partner selection and commercial readiness.

Commercial differentiation also depends on the ability to engage payers early, present clear value propositions grounded in patient-relevant outcomes, and implement creative contracting approaches when warranted. Organizations that invest in post-approval evidence generation, real-world data initiatives, and provider education are better positioned to drive adoption in constrained access environments. Ultimately, company success will hinge on integrated strategies that connect scientific novelty with pragmatic execution across development, regulation, manufacturing, and market access.

Actionable executive recommendations for industry leaders to accelerate therapeutic innovation, optimize market access strategies, strengthen payer and provider engagement, and build resilient supply and R&D operations

Industry leaders should align near-term operational choices with long-term strategic goals to accelerate meaningful advances in mesothelioma care. First, prioritize biomarker-driven development and incorporate translational endpoints in early-stage trials so that later-phase programs target responsive populations and reduce development attrition. Second, design adaptive trial architectures and platform studies to evaluate combinations efficiently, enabling faster identification of synergistic regimens while conserving patient and financial resources.

Third, strengthen supply chain resilience through supplier diversification, strategic onshoring where feasible, and long-term procurement agreements to mitigate exposure to trade policy shocks. Fourth, engage payers and HTA bodies early to establish evidence plans that address comparative effectiveness, quality-of-life metrics, and budget impact considerations, thereby smoothing the path to reimbursement. Fifth, invest in diagnostics and provider education to ensure that molecular stratification and referral pathways are in place when new therapies become available.

Finally, foster multi-stakeholder partnerships that bring together academic centers, patient advocacy groups, and commercial partners to co-create trial designs, patient support programs, and access initiatives. By integrating scientific rigor with pragmatic commercialization planning and stakeholder engagement, organizations can improve the probability of clinical and market success while enhancing patient access and outcomes.

Transparent research methodology outlining data collection approaches, analytic frameworks, expert advisory engagements, validation protocols, and limitations used to synthesize clinical, regulatory, and commercial insights

The research approach combines primary expert engagement, targeted literature synthesis, and structured analytic frameworks to ensure robust, defensible insights. Subject-matter experts spanning clinical oncology, pathology, regulatory affairs, and supply chain management were consulted to validate assumptions, interpret emerging clinical data, and surface operational implications. Peer-reviewed literature, regulatory guidance documents, and conference proceedings provided the clinical and scientific foundation for therapeutic and diagnostic trends.

Analytic processes included thematic synthesis of clinical trial designs, comparative assessment of mechanism-of-action portfolios, and qualitative evaluation of regional regulatory and reimbursement environments. Validation steps involved cross-referencing expert feedback with public regulatory decisions and clinical practice guidance to ensure coherence and minimize bias. Limitations were explicitly recognized, including variability in regional data availability, heterogeneity in real-world evidence maturity, and the evolving nature of late-breaking clinical findings.

Where data gaps existed, the methodology emphasized transparency about assumptions and recommended areas for follow-up research. The combined approach ensures that conclusions are grounded in multidisciplinary evidence while remaining actionable for commercial, clinical, and policy stakeholders seeking to navigate a rapidly changing mesothelioma landscape.

A decisive concluding synthesis that distills strategic inflection points, stakeholder obligations, policy considerations, and forward-looking priorities necessary to improve patient outcomes and therapeutic progress

The synthesis underscores a clear imperative: progress in mesothelioma will require harmonized advances across diagnostics, therapeutic innovation, and access pathways. Scientific progress in immuno-oncology and targeted agents offers real promise, but durable improvements in patient outcomes depend on precise patient selection, rigorous evidence generation, and the ability to translate trial findings into routine clinical practice. Stakeholders must therefore coordinate across development, regulatory, and payer domains to align incentives and evidence requirements.

Operational readiness, including manufacturing resilience and regional implementation capacity, is equally important to ensure that therapeutic advances are available to patients when approvals occur. In parallel, continued investment in biomarker development, translational research, and pragmatic trial designs will enable more efficient identification of impactful treatments. The combined focus on scientific rigor, commercial pragmatism, and collaborative problem-solving positions the field to deliver measurable improvements in care and to reduce barriers that currently limit patient access to promising therapies.

In closing, the path forward demands strategic alignment, sustained investment, and an unwavering commitment to patient-centered evidence that supports adoption and equitable access across care settings and regions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Malignant Mesothelioma Market, by Treatment Type

  • 8.1. Chemotherapy
    • 8.1.1. Pemetrexed Combinations
    • 8.1.2. Platinum Monotherapy
  • 8.2. Immunotherapy
    • 8.2.1. Ctla-4 Inhibitors
    • 8.2.2. Pd-1 Inhibitors
  • 8.3. Radiotherapy
  • 8.4. Surgery
  • 8.5. Targeted Therapy
    • 8.5.1. Egfr Inhibitors
    • 8.5.2. Mesothelin Targeted Agents
    • 8.5.3. Vegf Inhibitors

9. Malignant Mesothelioma Market, by Drug Class

  • 9.1. Antifolates
  • 9.2. Immune Checkpoint Inhibitors
    • 9.2.1. Ctla-4 Inhibitors
    • 9.2.2. Pd-1 Inhibitors
    • 9.2.3. Pd-l1 Inhibitors
  • 9.3. Kinase Inhibitors
  • 9.4. Monoclonal Antibodies
  • 9.5. Platinum Compounds

10. Malignant Mesothelioma Market, by Line Of Therapy

  • 10.1. First Line
  • 10.2. Second Line
  • 10.3. Third Line And Beyond

11. Malignant Mesothelioma Market, by Route Of Administration

  • 11.1. Intraperitoneal
  • 11.2. Intravenous
  • 11.3. Oral

12. Malignant Mesothelioma Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Malignant Mesothelioma Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Malignant Mesothelioma Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Malignant Mesothelioma Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Malignant Mesothelioma Market

17. China Malignant Mesothelioma Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Advanz Pharma Corp.
  • 18.7. Argenx SE
  • 18.8. AstraZeneca Plc.
  • 18.9. Boehringer Ingelheim GmbH
  • 18.10. Bristol-Myers Squibb Company
  • 18.11. Cipla Limited
  • 18.12. Dr. Reddy's Laboratories
  • 18.13. Eisai Co., Ltd.
  • 18.14. Eli Lilly and Company
  • 18.15. Emcure Pharmaceuticals Limited
  • 18.16. F. Hoffmann-La Roche Ltd.
  • 18.17. Fresenius Kabi AG
  • 18.18. Karyopharm Therapeutics Inc.
  • 18.19. Merck & Co., Inc.
  • 18.20. Mylan N.V.
  • 18.21. Nichi-Iko Pharmaceutical Co., Ltd
  • 18.22. Novartis AG
  • 18.23. Novocure GmbH
  • 18.24. Ono Pharmaceutical Co. Ltd
  • 18.25. Pfizer Inc.
  • 18.26. Polaris Pharmaceuticals, Inc.
  • 18.27. Sanofi S.A.
  • 18.28. Sun Pharmaceuticals Industries Ltd
  • 18.29. Wellona Pharma

LIST OF FIGURES

  • FIGURE 1. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MALIGNANT MESOTHELIOMA MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MALIGNANT MESOTHELIOMA MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PEMETREXED COMBINATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PEMETREXED COMBINATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PEMETREXED COMBINATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PLATINUM MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PLATINUM MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PLATINUM MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY EGFR INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY EGFR INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY MESOTHELIN TARGETED AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY MESOTHELIN TARGETED AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY MESOTHELIN TARGETED AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY VEGF INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY VEGF INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY VEGF INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ANTIFOLATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ANTIFOLATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ANTIFOLATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PLATINUM COMPOUNDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PLATINUM COMPOUNDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY THIRD LINE AND BEYOND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY THIRD LINE AND BEYOND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY INTRAPERITONEAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY INTRAPERITONEAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY INTRAPERITONEAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. GCC MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. GCC MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. GCC MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 193. GCC MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 194. GCC MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. GCC MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 196. GCC MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 197. GCC MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 198. GCC MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. GCC MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. G7 MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. G7 MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. G7 MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 223. G7 MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 224. G7 MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 225. G7 MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 226. G7 MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 227. G7 MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 228. G7 MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. G7 MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. NATO MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. NATO MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. NATO MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 233. NATO MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 234. NATO MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 235. NATO MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 236. NATO MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 237. NATO MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 238. NATO MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. NATO MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)